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Comparative Systems Analyses 
Reveal Molecular Signatures of 
Clinically tested Vaccine Adjuvants
Thorunn A. Olafsdottir1, Madelene Lindqvist1, Intawat Nookaew2,3, Peter Andersen4, 
Jeroen Maertzdorf5, Josefine Persson1, Dennis Christensen4, Yuan Zhang1, Jenna Anderson1, 
Sakda Khoomrung2, Partho Sen2, Else Marie Agger4, Rhea Coler6, Darrick Carter6, 
Andreas Meinke7, Rino Rappuoli8, Stefan H. E. Kaufmann5, Steven G. Reed6 & Ali M. Harandi1
A better understanding of the mechanisms of action of human adjuvants could inform a rational 
development of next generation vaccines for human use. Here, we exploited a genome wide 
transcriptomics analysis combined with a systems biology approach to determine the molecular 
signatures induced by four clinically tested vaccine adjuvants, namely CAF01, IC31, GLA-SE and Alum 
in mice. We report signature molecules, pathways, gene modules and networks, which are shared by or 
otherwise exclusive to these clinical-grade adjuvants in whole blood and draining lymph nodes of mice. 
Intriguingly, co-expression analysis revealed blood gene modules highly enriched for molecules with 
documented roles in T follicular helper (TFH) and germinal center (GC) responses. We could show that 
all adjuvants enhanced, although with different magnitude and kinetics, TFH and GC B cell responses 
in draining lymph nodes. These results represent, to our knowledge, the first comparative systems 
analysis of clinically tested vaccine adjuvants that may provide new insights into the mechanisms of 
action of human adjuvants.
Most vaccine antigens currently under investigation are based on highly purified subunits of pathogens or recom-
binant proteins and thus possess improved safety profiles. However, the shift from whole live attenuated or killed 
pathogens toward subunit vaccines necessitates the use of vaccine adjuvants that enhance, accelerate, prolong 
and/or modulate the desired immune responses1,2 for different pathogens and vaccinees3,4. The rational devel-
opment of new vaccines thus requires a thorough understanding of the modes of action of human vaccines and 
adjuvants.
Recently, systems biology approaches have successfully been used to study the mechanisms of action of a 
few vaccines approved for use in humans5 and, more recently, to study the modes of action of vaccine adjuvants 
(reviewed in ref. 6). However, the different experimental conditions used in adjuvant research often make it dif-
ficult to make direct comparisons. Furthermore, the most promising vaccine adjuvants can be difficult to gain 
access to for comparative analysis due to proprietary rights and conflict of interest issues. Within the EU-funded 
large collaborative project Advanced Immunization Technologies (ADITEC; grant agreement no.: 280873), an 
unprecedented opportunity emerged, which enabled a head-to-head comparison of some of the most promis-
ing vaccine adjuvants in clinical development. We have recently reported the results from the first comparative 
immunogenicity and protective efficacy testing of several human adjuvants7.
In the present study, we explored the molecular signatures of a panel of three adjuvants in clinical devel-
opment (CAF01, IC31 and GLA-SE) along with 2% Alhydrogel (Alum), the most commonly used adjuvant in 
licensed vaccines. CAF01 is a two-component liposomal adjuvant formulation composed of cationic liposomes 
formed of the dimethyldioctadecylammonium surfactant stabilized with trehalose dibehenate, a synthetic analog 
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to mycobacterial cord factor (trehalose dimycolate), and acting through mincle receptor activation8,9. IC31 is 
another two-component adjuvant consisting of the cationic peptide KLK combined with the Toll-like receptor 9 
(TLR9)-stimulatory oligodeoxynucleotide ODN1a10. Glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE) is 
a synthetic TLR4 agonist in a squalene-based oil-in-water emulsion11. Aluminum-based mineral salts have been 
considered the adjuvant of choice for vaccination against infections that can be prevented by an antibody (Ab) 
response and have been successfully used in several licensed vaccines12,13.
As a model antigen for the present study we chose H56, a clinical-grade multistage tuberculosis (TB) vac-
cine candidate under clinical evaluation (NCT01865487, NCT02375698, NCT02375698, NCT02503839, 
NCT01967134, NCT02378207). H56 is a fusion protein consisting of two well-characterized early secreted anti-
gens, antigen 85B (Ag85B) and early secreted antigen 6 (ESAT-6) and one latency-associated antigen Rv2660c 
from Mycobacterium tuberculosis14. This vaccine candidate has been shown to provide protective immunity in 
mice, in combination with the novel adjuvants tested in the present study (CAF01, IC31 and GLA-SE)7. It has 
furthermore provided protective immunity against TB in cynomolgus macaques in combination with IC3115, and 
CAF0116. H56 is in clinical development in combination with IC3117.
Using a genome-wide transcriptomics analysis of whole blood (WB) and draining lymph nodes (dLNs) at 
early time points after immunization combined with a systems biology approach, we identified both common and 
unique transcriptional profiles of the four adjuvants tested. Transcriptional changes associated with the induc-
tion of adaptive immune responses were commonly detected in WB for all adjuvants, whereas co-expression 
analysis identified distinct gene modules containing adjuvant-unique molecules that have previously been shown 
to be involved in germinal center (GC) reactions and/or the skewing of T helper cell responses. Guided by the 
co-expression analysis data, we therefore studied the ability of the four adjuvants to induce GC formation in 
the draining LNs following immunization in mice. These data showed that all of these adjuvants, when given in 
combination with H56 antigen, enhanced TFH and GC B cell responses compared with those of the H56 antigen 
alone, although kinetics and cell frequency differed among the different adjuvanted groups.
The results reported herein are, to our knowledge, the first comparative systems biology analysis of clinically 
tested vaccine adjuvants and thus could inform the rational development of vaccine adjuvants for human use.
Results
Transcriptomic profiles in WB and dLNs of mice induced by different clinically tested adjuvants. 
High-quality RNA samples extracted from WB and the dLNs of mice at four different time points (6 h, 24 h, 72 h 
and 168 h) after a subcutaneous (s.c.) injection of clinical-grade H56 with or without each clinical-grade adjuvant 
were subjected to genome-wide microarray analysis.
Mice receiving H56 alone were used as a control group for the groups receiving H56 in combination with 
any of the four adjuvants. Differentially expressed genes (DEGs) were thus defined as those with a significant 
(adjusted P value < 0.05 FDR) change in expression in an adjuvant group compared with H56 alone. Alum did 
not induce any appreciable changes in the transcripts from WB, except for the 72 h time point, where 89 DEGs 
were detected, most of which were shared by other adjuvants (Fig. 1a,b). Although the kinetics and magnitude 
of the transcriptional changes varied widely among the groups, the other three adjuvants (CAF01, IC31 and 
GLA-SE) induced more dramatic changes in the WB transcriptional profile than Alum. GLA-SE was the only 
adjuvant that had already induced significant transcriptional changes (5,858 DEGs) at 6 h, with the highest num-
ber of DEGs (11,460 DEGs) at 72 h (Fig. 1a). CAF01 induced a later onset (24 h) of gene expression in WB (1,152 
DEGs), and the highest number of significantly changed transcripts was observed at 72 h (4,490 DEGs) (Fig. 1a). 
The changes in the WB transcripts induced by IC31 were first observed and peaked at 24 h (3,191 DEGs) and 
decreased at 72 h (1,031 DEGs) (Fig. 1a). A higher proportion of downregulated transcripts was observed at the 
two early time points (6 h and/or 24 h), and greater numbers of upregulated transcripts were detected at 72 h for 
all adjuvants (Fig. 1c).
Next, we studied global changes in transcript profiles of dLNs in response to the different adjuvants. Overall, 
the transcriptional changes detected in dLNs were modest compared to those in WB. Alum induced limited 
changes in dLNs at 6 h. This number gradually increased at 24 and 72 h before peaking at 168 h (171 DEGs) 
(Fig. 1d). GLA-SE induced early changes in gene expression in dLNs at 6 h (1,787 DEGs), which increased at 24 h 
(9,440 DEGs) and 72 h (10,415 DEGs), followed by a decline at 168 h (5,420 DEGs), although the number of DEGs 
remained relatively high (Fig. 1d). Similar to the transcriptomic profile of WB, both CAF01 and IC31 induced 
much smaller numbers of DEGs in dLNs, with a later onset compared with GLA-SE. CAF01 caused changes in 
gene expression mainly at 24 h (460 DEGs) and only limited changes at 6 h, 72 h and 168 h (Fig. 1d). Similarly, the 
IC31-induced gene expression in dLNs peaked at 24 h (624 DEGs), decreased at 72 h, and then increased again at 
168 h (Fig. 1d). Few DEGs were observed in dLNs of all adjuvant-treated groups, although at 24 h, GLA-SE shared 
288 DEGs and 315 DEGs with IC31 and CAF01, respectively (Fig. 1e). The ratio between the up- and downreg-
ulated DEGs in dLNs showed similar trends for the different adjuvants across the different time points (Fig. 1f).
Overall, the adjuvants studied herein differed in terms of the magnitude and kinetics of the transcriptional 
changes induced in both WB and dLNs. In dLNs, GLA-SE induced the highest levels and the earliest onset of 
transcriptional changes, whereas both CAF01 and IC31 induced later and less detectable changes in the tran-
scriptional profile compared with GLA-SE. Alum induced the most subtle transcriptional changes in both WB 
and dLNs.
Gene functional patterns of WB revealed common and unique features of clinically tested 
adjuvants. To identify patterns of biological processes that were affected by the four adjuvants in WB, 
gene ontology (GO) enrichment mapping was performed for the DEGs of all adjuvants at the different time 
points. Three GO term groups were selected based on the clustering dendrograms, as explained in Materials 
and Methods. Distinct areas of enriched GO terms with upregulated DEGs were observed for all four adjuvants 
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at 72 h (Supplementary Fig. 1). Grouping of these GO terms revealed that most belonged to cellular, metabolic 
and immune system processes, as well as to responses to stimuli (Fig. 2a). Another distinct group of GO terms 
belonging to biological regulation and metabolic and cellular processes was significantly enriched in the majority 
of the upregulated DEGs at 72 h in the CAF01, IC31 and GLA-SE groups, but to a lesser extent in the Alum group 
(Fig. 2b). Many of the GO terms that were commonly changed in WB (mainly at 72 h) by the three novel adju-
vants were related to the initiation of adaptive immune responses (e.g., positive regulation of adaptive immune 
responses, positive regulation of B cell proliferation, and antigen processing and presentation).
Large numbers of GO terms were significantly enriched at early time points in the CAF01 (24 h and decreasing 
by 72 h) and GLA-SE groups (6 h and gradually decreasing by 168 h), with the majority of the DEGs being upregu-
lated. These GO terms were not significantly enriched in the IC31 group at 6 h or 24 h, and they mainly contained 
downregulated DEGs at 72 h. The majority of these GO terms belonged to biological regulation and response to 
stimuli associated with innate and inflammatory functions, such as positive regulation of monocyte chemotactic 
protein-1 production (MCP-1) and positive regulation of interleukin (IL)-6 and IL-1β production (Fig. 2c).
Induction of systemic responses of cytokines and chemokines by clinically tested adju-
vants. Next, we compared the patterns of cytokines and chemokines in sera of mice after administration of 
the adjuvants using a 23-plex luminex assay, including many known pro-and anti- inflammatory mediators. In 
line with the whole blood transcriptomics data, we observed the most subtle and greatest responses of cytokines 
and chemokines by Alum and GLA-SE, respectively (Fig. 3). GLA-SE induced elevated levels of the inflammatory 
cytokines IL-6 (fold change over H56 alone (FC) 25.61), IL12p70 (FC 25.73) and IL1α , (FC16.55) the neutrophil 
chemoattractant molecule KC (FC 34.72), the macrophage inflammatory protein MIP1-α (FC 10.23) and MCP-1 
(FC 9.97) as well as granulocyte colony stimulating factor (G-CSF) (FC 52.52) already at 6 h with IL1α (FC 20.46) 
and G-CSF (FC 36.81) remaining elevated at 24 h. In line with the transriptomics data, IC31 and CAF01 induced 
delayed cytokine responses compared with GLA-SE. Thus, CAF01 induced increased levels of IL-6 (FC 9.75), 
IL1α (FC 20.31), KC (FC 6.62) and G-CSF (FC 18.18) at 24 h whereas IC31 induced much lower levels of IL1α 
Figure 1. Overview of transcriptomic changes in whole blood and lymph nodes of mice in response to 
vaccine adjuvants. Groups of mice were immunized with H56 alone or in combination with Alum, CAF01, 
IC31 or GLA-SE. The numbers of differentially expressed genes (DEGs) (compared with the H56 alone group) 
in the whole blood (WB) (a) and lymph nodes (LNs) (d) are shown as line plots. The Venn diagram depicts the 
numbers of unique and shared DEGs in WB (b) and LNs (e) at 24 h and 72 h. Volcano plots illustrate numbers of 
significantly downregulated (blue dots) and upregulated (red dots) DEGs for each adjuvant in WB (c) and LNs 
(f) over time.
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Figure 2. Analysis of gene ontology terms revealed shared and unique molecular signatures of vaccine 
adjuvants. A directional gene set enrichment analysis of the gene ontology (GO) terms in the DEGs was 
performed using the PIANO package. At 72 h, a group of GO terms was identified as commonly upregulated by 
all four adjuvants (a), and another group of GO terms was commonly upregulated by CAF01, IC31 and GLA-SE 
(b). A third group of GO terms was commonly upregulated by CAF01 and GLA-SE at early time points, whereas 
it was heavily downregulated by IC31 at 168 h (c). The heatmap shows the value of the enrichment score 
(− log10(enrichment P value)). The GO terms are color-coded to illustrate the direction of the gene expression 
changes in the majority of genes included in the respective GO term, i.e., red for upregulation and blue for 
downregulation.
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(FC 5.24) and was the only adjuvant inducing high levels of IL-9 (FC 13.57). Taken together, these results, in line 
with the transcriptomics data, show that GLA-SE induces early and strong pro-inflammatory responses, and that 
CAF01 and IC31 mount delayed pro-inflammatory cytokine responses of smaller magnitude compared to those 
of GLA-SE.
Co-expression analysis in WB revealed shared and unique features of clinically tested adjuvants. 
Next, a weighted gene co-expression network analysis of DEGs across all time points for each adjuvant was con-
ducted to identify the most highly affected gene modules (groups of highly co-expressed genes). Co-expression 
analyses utilize interaction patterns among significantly changed genes to reduce high-dimensional microarray 
datasets in an unbiased way. The co-expression analysis of DEGs in WB identified six different co-expressed mod-
ules for CAF01, IC31 or GLA-SE; each module was assigned a color code (Fig. 4a). The modules contained var-
ious numbers of genes, ranging from 77 genes (GLA-SE red module) to 566 genes (GLA-SE turquoise module). 
No co-expression module was identified for Alum due to its limited number of DEGs. Next, gene lists were 
generated from each module, and Ingenuity Pathway Analysis (IPA) was employed to identify enrichments in 
known biofunctions. The significantly changed biofunctions for each module and the associated DEGs are listed 
in Supplementary Table 1. For each adjuvant we decided to focus on those modules having most biofunctions 
associated with innate responses (CAF01; brown, Fig. 4b. GLA-SE; red, Fig. 4f) and induction of adaptive immu-
nity (CAF01; turquoise, Fig. 4c. IC31; brown, Fig. 4d and turquoise, Fig. 4e. GLA-SE; yellow, Fig. 4g).
Whereas biofunctions associated with innate immune responses were scattered across different modules of 
the IC31 group (Supplementary Table 1), both GLA-SE and CAF01 had distinct modules containing molecules 
involved in innate inflammatory and phagocytosis responses (brown for CAF01 and red for GLA-SE, Figs 4b 
and f). For both adjuvants, the majority of the biofunctions were associated with cellular movement, such as 
leukocyte migration, chemotaxis of myeloid cells, chemotaxis of phagocytes and cell movement of neutrophils. 
Macrophage-inducible C-type lectin (Mincle) transcripts (Clec4e) were noted in many of the most highly signif-
icant innate biofunctions for both CAF01 (brown module) and GLA-SE (red module) (Supplementary Table 1). 
Mincle was first described as being induced upon lipopolysaccharide stimulation18 and has recently been reported 
as a key receptor for the CAF0119.
The brown module with the most highly significant biofunctions in the IC31 group included categories of 
biofunctions that are directly linked to adaptive immune responses, such as humoral immune response and 
cell-mediated immune response. Furthermore, many of the other categories, such as cellular development 
and hematological system development, contained biofunctions associated with the initiation of adaptive 
immune responses, including proliferation of lymphocytes and quantity of lymphocytes, respectively. Pou class 
2-associating factor 1 (Pou2af1), a molecule shown to play an important role in multiple stages of B cell develop-
ment and GC formation in mice upon immunization with T cell-dependent antigen20,21, was one of the transcripts 
involved in most biofunctions of adaptive immunity (Fig. 5b). Other biofunctions associated with the activation 
of adaptive immune responses and lymphocyte differentiation were detected in several other modules in the IC31 
group, particularly the turquoise module (Fig. 4e and Supplementary Table 1).
Figure 3. Induction of serum responses of cytokines and chemokines by clinically tested adjuvants. The 
radar plots show fold changes of cytokines and chemokines induced by different adjuvants over those of the H56 
alone at 6 h (blue line) and 24 h (red line). The protein color codes are: cytokines (violet), chemokines (yellow) 
and growth factors (blue). Note the different scale for GLA-SE compared with the other adjuvant groups.
www.nature.com/scientificreports/
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For CAF01, biofunctions associated with lymphocyte activation were most abundant in the turquoise mod-
ule, with the majority related to T cells and antigen-presenting cells (APCs) across different categories, such 
as differentiation of myeloid dendritic cells (DCs), differentiation of CD4+ T lymphocytes and class switching 
of B lymphocytes (Fig. 4c). Transcripts for the cytokine Tgfb and the transcription factor Batf were among the 
co-expressed molecules that were most commonly associated with the differentiation of APCs and lymphocytes 
in the CAF01 group (Fig. 5a). Batf is a transcription factor with important roles in the development of Th17, Th2 
and TFH cells, as well as in the differentiation of Ab-producing B cells22.
For GLA-SE, most of the highly significant biofunctions associated with lymphocyte activation were detected 
in the yellow module. These biofunctions included differentiation of T lymphocytes, function of B lymphocytes 
and quantity of TFH cells (Fig. 5c and Supplementary Table 1). The biofunctions associated with lymphocyte 
activation and differentiation in the yellow module of GLA-SE in WB included transcripts of nuclear factor of 
activated T cells 1 and 2 (Nfatc1 and Nfatc2) and IL-21 receptor (Il21r) (Fig. 5c), which have known functions in 
T cell activation, TFH activation and GC reactions.
Overall, co-expression analysis of DEGs in WB revealed that CAF01, IC31 and GLA-SE had distinct gene 
modules associated with biofunctions of adaptive immune responses, and that these gene modules contain mole-
cules with documented roles in mounting characteristic T cell responses induced by each adjuvant.
Co-expression and biofunction analysis of dLNs. The co-expression analysis of DEGs in dLNs identi-
fied distinct modules for IC31 and GLA-SE. However, due to the limited numbers of significant DEGs in dLNs in 
the Alum and CAF01 groups, the co-expression analysis for these adjuvants revealed no distinct modules. Two 
modules were defined for IC31 and 11 modules for GLA-SE, with variable numbers of transcripts ranging from 
70 DEGs in the blue module for IC31 to 774 DEGs in the turquoise module for GLA-SE (Supplementary Table 2). 
The small blue module of IC31 contained molecules involved in immune cell trafficking, such as the accumula-
tion of granulocytes and recruitment of leukocytes, as well as the initiation of adaptive (especially cell-mediated) 
immune responses, including the density and recruitment of T lymphocytes. The turquoise module of GLA-SE 
contained the most highly significant biofunctions, many of which were associated with infectious diseases, 
inflammatory responses and hematological system development and function. Other significantly changed bio-
functions for GLA-SE associated with the initiation of immune responses following vaccination, included the 
cellular immune response, quantity of APCs, and quantity of IgG. A few other immune-related biofunctions were 
spread across the different modules of the GLA-SE group, including the quantity of IgG2a and development of 
Figure 4. Co-expression analysis of DEGs identified common and unique biofunctions of vaccine 
adjuvants. Dendrogram from the gene co-expression analysis. Modules of significantly co-expressed genes were 
assigned different colors (a). Selection of the biofunction identified by IPA for the gene list of the brown and 
turquoise modules for CAF01 (b and c) and IC31 (d and e) as well as the red and yellow modules for GLA-SE 
(f and g). The size of each bubble is proportional to the number of DEG molecules involved in the given 
biofunction. Biofunctions belonging to the same category are color-coded.
www.nature.com/scientificreports/
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Figure 5. Co-expression analysis revealed adjuvant-specific molecules involved in adaptive immunity-
related biofunctions. Relationship of the selected B and T cell-related biofunctions with the DEGs induced by 
CAF01 (a), IC31 (b) and GLA-SE (c) as identified by coexpression analysis. Biofunctions shown in red color.  
Cytokine/Growth factor,  Enzyme,  Kinase,  Transcriptional regulator,  Transmembrane receptor,  
Other.
www.nature.com/scientificreports/
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TFH cells in the green-yellow module. The significantly changed biofunctions for each module and the associated 
DEGs in dLNs are listed in Supplementary Table 2.
Adjuvant-mediated induction of TFH cell population in dLNs. The unsupervised co-expression anal-
ysis described above identified adjuvant-specific gene modules that included molecules with known functions in 
TFH cells and/or the formation of GCs. This finding prompted us to study the impact of these human adjuvants 
on GC reactions and TFH cell responses in dLNs following immunization with H56 and the adjuvants. Mice were 
s.c.-immunized once with H56 alone or in combination with any of the four adjuvants. During the first 10 days a 
10-fold expansion of the total dLN cell numbers was observed in the GLA-SE adjuvant-treated mice compared to 
the H56 group alone, whereas a more modest expansion ranging from 2- to 5-fold was induced by the other three 
adjuvants over the same time period (Fig. 6a). This suggests a very rapid and broad immune induction in the 
local dLN by GLA-SE, which was also indicated by the massive number of DEGs in both dLNs and blood within 
the first 72 h after immunization (Fig. 1). The TFH cells in dLNs on days 3, 5, 7, 10, 12 and 14 after immunization 
(Fig. 6b) were studied by evaluating the frequencies of CXCR5hi, PD-1hi CD4+ T cells (Fig. 6c). The frequencies 
and numbers of TFH cells remained low in the H56-immunized animals throughout the study. In contrast, all of 
the tested adjuvants enhanced TFH cell frequencies, and the most increase in frequencies of TFH cells relative to 
CD4+ T cells compared with H56 alone were observed 7 days after immunization. Similarly, adjuvant induced 
Figure 6. Induction of T follicular helper cell responses in draining LNs by vaccine adjuvants. Groups of 
mice were s.c. immunized with H56 alone or in combination with an adjuvant. Draining LNs were collected on 
days 3, 5, 7, 10, 12 and 14 after immunization, and the number of live cells was counted using the trypan blue 
exclusion assay (a). Frequency of T follicular helper (TFH) cells among the CD4 T cells and the total number 
of TFH cells were evaluated by flow cytometry (b). TFH cells were gated as PD1high CXCR5high, as shown by 
the representative plots (c). Graphs summarizing the frequency of TFH cells among the CD4 T cells (d) and 
the number of TFH cells on day 7 (e). The frequency of GL7+ TFH cells (f) on day 7. n = 5–6 mice at each time 
point, except for panel f (n = 3). The data from two independent experiments were pooled. The dots indicate 
individual values and are shown as means with error bars that represent the ± SEM. Significance was calculated 
using the Kruskal-Wallis test.
www.nature.com/scientificreports/
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increase in total number of TFH cells was observed on day 7 compared with H56 alone, followed by a dramatic 
decrease on day 10 for IC31 and day 12 for GLA-SE and CAF01 (Fig. 6b). The mean frequencies of TFH cells 
were comparable among the different adjuvant groups on day 7, although the intra-group variations ensured that 
only the Alum and IC31 groups showed a statistically significant increase in TFH frequency compared to H56 
alone (Fig. 6d). Higher numbers of TFH cells were only detected in the GLA-SE group (P < 0.01), but with a trend 
toward higher numbers in the other three adjuvant groups also when compared with the H56 alone group, reflect-
ing a difference in total cell numbers in dLNs among the different adjuvant groups (Fig. 6e). Fully differentiated 
GC TFH cells have been shown to express GL7 (CXCR5+ GL7+), in contrast to the TFH (CXCR5+ GL7−) cells 
located outside of the GC23. High proportion of TFH cells in the dLNs of the different adjuvant groups expressed 
GL7, indicating that most of the cells falling within our TFH gate were fully differentiated with the highest fre-
quency of GL7 TFH cells observed in CAF01 and GLA-SE groups on day 7 (Fig. 6f).
Taken together, these results show that all of the tested adjuvants enhanced the frequencies of TFH cells com-
pared with H56 alone. Although a big variation in the TFH induction kinetics was seen among the adjuvants, no 
significant difference in frequencies was observed. GLA-SE induced the highest absolute numbers of TFH cells 
within the sampling period reflecting a significantly larger expansion of the dLN after vaccination when com-
pared to the other adjuvants. The major proportion of adjuvant-induced TFH cells was also shown to express GL7 
following immunization, indicating that these cells had completely differentiated into TFH cells.
Clinically tested adjuvants induced different GC reactions. TFH cells induce and regulate GC for-
mation as well as B cell maturation and differentiation culminating in high-affinity Ab responses. We investigated 
the induction of GC B cells in dLNs on days 3, 5, 7, 10, 12 and 14 after immunization, i.e., the same time points 
used in the TFH cell experiment described above. Although the induction of TFH cells peaked 7 days after immu-
nization for all the adjuvant groups, the differentiation of B cells into GC B cells peaked on day 10 in terms of 
both frequency and numbers (Fig. 7a). GC B cells were gated as GL7+ and CD95+ among the CD19+ B cells and 
represented a clearly distinct population on day 10 in all of the adjuvant groups (Fig. 7b). Significantly higher 
frequencies of GC B cells were observed in the Alum (P < 0.01) and GLA-SE (P < 0.05) groups compared with 
the group receiving H56 alone, whereas more variation was observed in the CAF01 and IC31 groups (Fig. 7c). 
The greatest increase in the total number of GC B cells was observed in the GLA-SE (P < 0.001) group compared 
with the H56 group (Fig. 7d). Furthermore, GLA-SE (P < 0.05) was the only adjuvant that enhanced the number 
of cells with the PC phenotype (CD138+ B220int/low) at the early time points (Fig. 7e). Next, we examined the for-
mation of GCs in dLNs on day 10 after immunization using immunohistochemistry with antibodies against GL7 
(blue), B220 (red) and CD4 (green) (Fig. 7g). Immunohistochemical staining revealed that although the number 
of GCs in dLNs did not differ significantly among the immunized groups, all of the mice immunized with adju-
vant plus H56 showed an increased GC size compared with the H56 alone-immunized mice (Fig. 7f). Statistically 
significant differences were only observed for the CAF01 and GLA-SE groups (P < 0.05) (Fig. 7f). The induction 
of GC B cells and PCs strongly correlated with the induction of TFH cells (Fig. 6h).
Although GC formation lagged behind TFH cell induction in mouse dLNs following immunization with the 
H56 antigen and the adjuvants, these results reveal that the two processes were correlated. Interestingly, all of the 
tested adjuvants enhanced GC formation, as demonstrated by the GC size and GC B cell frequency. However, dif-
ferences were observed in the adjuvants’ ability to enhance total numbers of GC B cells and early PC phenotypes 
in the dLNs.
Discussion
Systems biology approaches have recently been employed to define early signatures of immune responses induced 
by different human vaccines and adjuvants (reviewed in refs 5 and 6). However, direct comparative analyses of 
different human adjuvants have been hampered by a lack of uniformity in experimental design and data analysis, 
combined with the unavailability of proprietary adjuvants. Herein, we report the early molecular signatures in 
mouse WB and dLNs of three clinically tested vaccine adjuvants, namely CAF01, IC31 and GLA-SE, along with 
Alum.
Wide variation in transcriptional changes in both magnitude and kinetics was observed among these adju-
vants, with Alum and GLA-SE inducing the smallest and largest numbers of transcriptional changes, respectively, 
in both WB and dLNs. These results are in accordance with a previous report showing that immunization with 
Alum induced only limited transcriptional changes in WB and dLNs when compared with GLA-SE24. CAF01 and 
IC31, on the other hand, induced fewer transcriptional changes in WB and dLN compared to GLA-SE. CAF01 
and IC31 were previously shown to form a depot at the injection site with only slightly increased activity in the 
dLN over a prolonged time period25,26, and therefore it is plausible that a higher magnitude of gene expression 
could be observed at their injection site. The massive transcriptional changes induced by GLA-SE both in WB 
and in dLNs correlated with a much higher expansion of the total cell number in the dLNs of the GLA-SE group 
compared with those of the other three adjuvants. The differences between the CAF01 and IC31 groups and 
the GLA-SE group in terms of the overall kinetics and magnitude of in vivo transcriptional changes presuma-
bly reflect the different cell subpopulations targeted by the adjuvants and the in vivo kinetics of the adjuvants. 
Recently, GLA-SE was found to induce neutrophils to engulf antigen at injection site and travel to subcapsular 
lymphatics as well as T cell areas of the dLNs within 24 hours where they produced high amounts of IFN-γ 27. 
Further, GLA-SE was shown to dramatically enhance the number of activated CD11c+ GR1+ myeloid DCs in 
mouse LNs within 24 h after immunization24 whereas CAF01 and IC31 were found to target a minute number of 
vaccine-associated DCs in vivo over a period of 2 weeks in mice25,26,28. These observations could, at least in part, 
explain the limited transcriptional changes induced by IC31 and CAF01 in both WB and dLNs as compared to 
GLA-SE. Furthermore, the early onset of transcriptional changes induced by GLA-SE in the dLNs (6 h) is in line 
with a previous report24. Nevertheless, the massive cell infiltration and early transcriptional changes associated 
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with inflammatory responses induced by GLA-SE returned to the baseline levels within 7 days after administra-
tion. It is noteworthy that all of these adjuvants have previously been reported to be well tolerated with acceptable 
safety profiles in human trials.
Co-expression analyses have been widely used to elucidate the molecular mechanisms of various immuno-
logical properties, including human blood transcriptome modules, following vaccination29,30. The co-expression 
analysis of DEGs in WB presented herein revealed both common and unique biofunctional signatures for the 
three novel adjuvants. Both CAF01 and GLA-SE induced modules with biofunctions that were related to innate 
immune responses, such as the recruitment of various innate cells, chemotaxis and phagocytosis. IC31, on the 
other hand, did not exhibit a distinct module of DEGs associated with innate immune responses, and the corre-
sponding DEGs were scattered across different modules. This is in accord with the observation that IC31 was the 
only adjuvant among the three without highly upregulated DEGs belonging to GO terms for innate inflammatory 
responses. The observed limited pro-inflammatory transcript expression is in line with a previous report that 
IC31 mainly targets monocyte-derived DCs by increasing the level of IFN-β and limiting the production of the 
pro-inflammatory cytokines TNF-α and IL-631.
Gene modules in WB that were mainly associated with adaptive immune-related biofunctions were identified 
for all four adjuvants. An extensive immunological comparison of the same four adjuvants was recently reported 
by Knudsen et al. revealing that the adjuvants induced different CD4+ T cell polarization as well as IgG Ab sub-
class switching independent of the choice of antigen7. Our analyses of the main molecules involved in biofunc-
tions related to adaptive immunity revealed intriguing differences that might explain the observed differences in 
B and T cell responses induced by the different adjuvants.
Interestingly, our co-expression analysis identified adjuvant-specific WB gene modules containing genes with 
known function in GC TFH cell-mediated B cell responses, including Nfatc1, Nfatc2 and IL21R (induced by 
GLA-SE)32–34, Batf (induced by CAF01)22 and Pou2af1 (induced by IC31)20,21. All four adjuvants tested herein 
Figure 7. Germinal center reactions in draining LNs induced by adjuvants. Mice were s.c. immunized 
with H56 alone or in combination with the indicated adjuvants. Draining LNs (dLNs) were collected on days 
3, 5, 7, 10, 12 and 14 after immunization, and the frequency of germinal center (GC) cells among the CD19+ 
B cells and the total number of GC B cells were evaluated by flow cytometry (a). Germinal center (GC) B 
cells were gated as GL7+ CD95+ among the CD19+ B cells, as shown by the representative plots (b). Graphs 
summarizing the frequency (c) and total numbers (d) of GC B cells as well as total numbers (e) of cells with the 
plasma cell (PC) phenotype CD138+ B220int/low on day 10 after immunization. Column plots showing the 
number of GCs and size of the GC area per section in μ m2 counted from 18 dLNs sections from each group (f). 
One representative section of a dLN showing immunohistochemical staining for GL7 (blue), B220 (red), and 
CD4 (green) on day 10 after immunization (g). The number of GCs per section was determined by microscopy, 
and the surface (μ m2) of the GC was measured using ImageJ 1.49v software. Correlations between the numbers 
of TFH cells and GC B cells on day 10 for all groups are shown on the left, and the numbers of TFH cells and 
PC cells on day 10 are shown on the right (h). The results are expressed as the means ± SEM and significance 
was calculated using the Kruskal-Wallis test. Correlations were assessed using Spearman’s rank test. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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induced elevated TFH cell differentiation in dLNs 7 days after co-administration with H56, when compared to 
H56 alone. This was followed by induction of GC B cells peaking on day 10. It should be noted that the small 
percentages of TFH and GC B cells detected in the dLN of the H56 alone group support our previous findings 
in which H56 alone was found immunogenic, albeit its immunogenicity was dramatically enhanced when com-
bined with CAF01, GLA-SE and IC317. GLA-SE induced the highest numbers of TFH cells and GC B cells at 
day 10, which agrees with a recent report on the ability of GLA-SE in induction of a strong Ab response already 
after one immunization, whereas IC31, CAF01 and Alum induced significant Ab responses only after two or 
three immunizations7. The squalene-based adjuvant, MF59, has been reported to reach the dLNs within 6 h fol-
lowing co-injection with Ag where it promoted retention of intact Ag entrapped in immune complexes within 
macrophages translocating the vaccine to the follicular DCs pivotal in initiating the GC reaction35,36. The close 
resemblance between the SE part of GLA-SE and MF59 suggests that similar processes could be mediated by the 
two adjuvants. Thus, it is likely that the broad activation of dLN-resident cells in response to GLA-SE may play a 
role in the massive dLN expansion, the strong transcriptional changes and the early induction of GC B cells and 
PCs reported herein and the subsequent Ab response as previously reported7. Our data also support the notion 
that the number of TFH cells strongly correlates with the adjuvant-induced B cell responses37.
It has previously been reported that IC31 and CAF01 induce durable and potent characteristic CD4+ T cell 
responses in mice and humans7,8,38–40. Interestingly, Batf and Tgfb, with documented roles in Th17 differentiation, 
were among the co-expressed molecules within adaptive immune-related biofunctions for the Th17-inducing 
adjuvant CAF0141,42. Further, genes involved in Th1 differentiation such as Pou2af1 and Btla, were among the 
co-expressed molecules for the Th1-tilting adjuvant IC3143. Nevertheless, we were unable to perform a statistical 
correlation analysis on the early molecular signatures and immunological readouts due to the lack of stratified 
immune responses in inbred mice.
In line with other publications, we observed subtle transcriptional changes induced by Alum compared with 
the other tested adjuvants, despite the ability of Alum in mounting a potent antibody response and the induc-
tion of TFH and GC B cell responses in the draining lymph nodes of mice24,44–46. Mode of action of Alum is 
incompletely understood and suggested mechanisms of action include increased Ag uptake, recruitment of innate 
inflammatory cells, such as neutrophils, eosinophils, inflammatory monocytes, myeloid DCs and plasmacytoid 
DCs to the site of injection, and subsequent activation of innate immune responses through various danger sig-
nals47,48. Although our systems biology analysis of Alum induced response presented herein add to the growing 
body of evidence in the literature on the mode of action of Alum, further studies are needed.
In summary, the head-to-head comparative transcriptomics and systems biology analyses of clinical-grade 
adjuvants reported herein have revealed gene expression profiles, biological pathways, biofunctions and gene 
modules in mouse WB and dLNs that are shared by or exclusive to the different adjuvants. We could also identify 
characteristic blood gene modules that were highly enriched for adaptive immune-related biofunctions, including 
molecules with documented roles in TFH and GC responses. These observations were supported by immuno-
logical analyses showing that, although with different magnitude, all groups receiving adjuvanted H56 showed 
enhanced TFH and GC responses in dLNs, compared with the H56 antigen alone. These results provide new 
insights into the mechanisms of action of three clinically tested adjuvants, along with Alum, and may inform 
rational development of new adjuvants for human use.
Materials and Methods
Animals. Six- to eight-week-old female CB6F1/OlaHsd mice (Harlan Laboratories, The Netherlands) were 
housed in ventilated cages with free access to food and water. All animals were housed under standardized path-
ogen-free conditions at the Experimental Biomedicine Animal Facility, University of Gothenburg.
Ethics Statement. The use of mice was performed in accordance with the regulations set forth by the Ethical 
Committee for Animal Experimentation in Gothenburg, Sweden and in accordance with European Community 
Directive 86/609. All the techniques and procedures were refined to provide for maximum comfort and minimal 
stress to mice. Experiments performed were approved by the Ethical Committee for Animal Experimentation in 
Gothenburg, Sweden under license 64/2015.
Adjuvants and antigen. The effects of the adjuvants were evaluated with 5 μ g of clinical-grade 
Mycobacterium tuberculosis H56 fusion protein provided by Statens Serum Institute (SSI, Denmark). The follow-
ing clinical-grade adjuvants were tested: Alhydrogel 2% (hereafter called Alum) provided by Brenntag Biosector 
(Denmark), CAF01 from SSI, IC31 from Valneva Austria GmbH (Austria), and GLA-SE from Infectious Disease 
Research Institute (Seattle, WA, USA). The adjuvants and antigens were combined strictly according to the man-
ufacturers’ recommendations. Alum was diluted to 3.4 mg/ml of aluminum in saline. Then, H56 in saline was 
added to Alum at a 1:1 ratio (v/v) and rotated at 4 °C overnight for adsorption. CAF01 was mixed with H56 in Tris 
buffer (10 mM, pH 7.4) at a 1:1 ratio (v/v) and gently vortexed. IC31 was mixed with H56 in phosphate-buffered 
saline (PBS) such that the final concentration of each dose was 100 nmol KLK/4 nmol ODN1a, and then the mix-
ture was gently inverted several times to ensure a homogeneous suspension. GLA-SE was vortexed with H56 in 
PBS to obtain a final concentration of 5 μ g/dose. All vaccines were used within 2 h of final preparation.
Study design and organ collection. Mice were lightly anesthetized with isoflurane (Baxter Healthcare) 
before immunization with H56 with or without adjuvant, as described above. Each mouse received a total volume 
of 100 μ l of the vaccine mixture injected s.c. on both sides of the base of the tail. Each group included 28 mice. A 
group of non-immunized mice (n = 7) were sacrificed and served as a naïve control group (time point 0 h). Seven 
mice from each group were sacrificed at each of the four time points (6 h, 24 h, 72 h and 168 h) after immuniza-
tion. WB was collected from the axillary plexus in PAXgene RNA stabilizer (Qiagen GmbH, Germany) such that 
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the final ratio of stabilizer to blood was maintained at 2.76, as recommended by the manufacturer. Immediately 
after bleeding, the mice were sacrificed by cervical dislocation and the inguinal LNs were harvested in 1 ml of 
RNAlater (Qiagen).
In another set of experiments, groups of mice were immunized with the vaccine formulations described above. 
dLNs were collected 3, 5, 7, 10, 12 and 14 days after primary immunization to evaluate effects of the different 
vaccine formulations and immunization schemes on TFH cells and humoral responses.
RNA extraction. RNA was extracted from dLNs and WB using the RNeasy Mini QIAcube kit (Qiagen) and 
PAXgene kit (Qiagen), respectively, according to the manufacturer’s instructions. Briefly, dLNs were homoge-
nized in 350 μ l of RLT buffer with metal beads in a TissueLyser II for 2 min. Further homogenization was per-
formed by adding the samples to QIAshredder columns, followed by centrifugation at 14,000 rpm for 2 min. The 
samples, DNase from an RNase-free DNase kit (Qiagen), 70% ethanol and all the necessary reagents from the 
appropriate RNA extraction kits were then added to the QIAcube, according to the manufacturer’s protocol. The 
extracted RNA was kept on ice upon extraction, followed by an assessment of the RNA concentrations using a 
Nanodrop spectrophotometer (Thermo Scientific, USA). All the samples were examined on an Agilent 2200 
TapeStation (Agilent Technologies, USA) to check the quality by measuring the RNA integrity number (RIN). 
High-quality RNA samples, which were defined as having a 260/280 ratio of approximately 2 and an RIN > 8, 
were used in downstream applications.
Whole-genome microarray analysis. High-quality RNA samples from WB and dLNs were subjected 
to a whole-genome microarray analysis on an Agilent platform (Agilent Technologies). The RNA was labeled 
with a Fluorescent Linear Amplification Kit according to manufacturer’s instructions. The quantity and labeling 
efficiency were verified before the samples were hybridized to whole-genome 8 × 60 k mouse expression arrays, 
which were scanned at 5 μ m using an Agilent scanner. Image analysis was performed with Feature Extraction 
software (version 11.5.1.1, Agilent Technologies) to generate raw microarray data.
Microarray data acquisition and analysis. Microarray data were pre-processed and normalized using 
the limma package for the R suite. The raw data were first corrected for background using the “normexp” method. 
Background-corrected signals were normalized together using the quantile method. The normalized gene sig-
nals were further evaluated for differential gene expression using the moderate Student’s t-test to compare the 
different groups with the control group at each time point, and the P values were further adjusted for multiple 
testing using the Benjamini-Hochberg method. Changes in expression induced by the adjuvants were calculated 
by dividing the log2 expression value of each individual adjuvant-treated group by the log2 expression value of the 
group receiving H56 alone at any given time point. A directional gene set GO enrichment analysis was performed 
using the PIANO package49. The results were plotted as a heatmap of the enrichment score (− log10 (enrichment P 
value)). To identify global functional profiles, GO terms were traced back to their corresponding main GO hierar-
chy. GO relationships were retrieved from go-basic.obo (released November 10, 2014), and the different levels of 
the GOs were generated using a custom script. Differential gene expression (adj P value < 0.05) was further used 
to identify concerted responses using a gene co-expression analysis method called weighted gene co-expression 
analysis50. This analysis was performed in the R suite using the R package WGCNA51. IPA software (Qiagen) was 
used to evaluate biofunctions associated with gene lists derived from co-expression analyses. Visualization of the 
selected co-expressed modules was performed with Cytoscape software52. The complete set of the microarray data 
was deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number 
GSE85339 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE85339).
Multiparameter flow cytometric analysis. Inguinal LN cells were washed with PBS and stained with 
an amine-reactive viability dye (LIVE/DEAD Yellow, Invitrogen). For the T cell Ab panel, cells were stained with 
purified rat anti-CXCR5 Ab (2G8, BD Pharmingen) for 1 h at 4 °C, followed by a goat anti-rat biotin Ab (Jackson 
ImmunoResearch) for 30 min at 4 °C. Surface staining was performed together with streptavidin (Biolegend) 
labeling at 4 °C for 30 min using the following antibodies: CD3 (17A2), CD4 (RM4-5), PD-1 (29F.1A12), CD44 
(BD Pharmingen), CD19 (6D5), CD138 (281-2), B220 (RA3-6B2), GL7 (GL7), and CD95 (Jo2, BD Pharmingen). 
All antibodies were from Biolegend unless otherwise indicated. Samples were acquired on an LSR II (BD 
Biosciences) flow cytometer. Compensation was performed using compensation beads labeled with a single Ab 
(UltraCompBeads, eBioscience). The data were analyzed using FlowJo version 9.2 (TreeStar Inc.). Lymphocytes 
were defined by FSC/SSC, and doublets were excluded by FSC-A/FSC-H gating. Live cells were gated as negative 
for Yellow Live/Dead staining, and CD4 T cells were defined as CD3+, CD19−, and CD4+. B cells were categorized 
as distinct subsets of GC B cells (CD3−, CD19+, CD95+, and GL-7+) or PCs (CD3−, B220int/low, and CD138+).
Immunohistochemistry. Inguinal LNs (n = 3) were collected in Histocon (HistoLab) 10 days after immu-
nization, embedded in Tissue-Tek OCT (Sakura), snap-frozen in isopentane cooled in liquid N2 and stored at 
−80 °C until they were cut into 7 μ m sections. The sections were fixed in acetone and stored at −20 °C until stain-
ing. Three sections of different depths from each mouse were stained. Slides were blocked with 10% goat serum 
and stained overnight with biotinylated anti-B220 (RA3-6B2, BD Pharmingen), anti-CD4-FITC (L3T4, eBiosci-
ence) and anti-GL-7-eFluor660 (GL-7, eBioscience) at 4 °C, followed by a 1-h incubation with streptavidin-Alexa 
Fluor 594 (Life Technologies) at room temperature. Slides were mounted with Fluorescent Mounting Medium 
(Dako) and examined with a Zeiss Axio Imager.Z2 microscope. Images were acquired with Zeiss Zen Pro soft-
ware. The number of GCs per section was counted under the microscope, and the GC area in each section was 
quantified using ImageJ 1.49 v software (NIH, USA).
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Assessment of cytokine and chemokines in serum. Serum samples were collected at 6 h and 24 h and 
stored at − 20 °C until analyzed with a Bio-Plex Pro Mouse Cytokine 23-plex Assay (Biorad). The luminex assay 
was performed according to the manufacturer’s protocol and run on MagPix equipment (Invitrogen). Fold change 
(FC) calculation of proteins induced by the different adjuvants were calculated by dividing the mean values of 
each protein in different adjuvant groups by the mean values of those of the H56 alone group.
Statistical analyses. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software). 
A Kruskal-Wallis post-test was used with a 95% confidence interval to compare multiple groups. Spearman’s 
correlation analysis was performed, and P values < 0.05 were considered significant.
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